BioCentury
ARTICLE | Company News

Dr. Reddy's endocrine, cardiovascular news

October 3, 2005 7:00 AM UTC

RDY spun out Perlecan Pharma Private Ltd. to develop therapeutics for endocrine and cardiovascular diseases. The newco takes with it four NCEs: DRF 10945, a non-fibrate, predominantly PPAR alpha agonist that has completed Phase I testing for dyslipidemia; RUS 3108, a perlecan inducer that is in Phase I testing for atherosclerosis; DRF 11605, a PPAR alpha, delta and gamma agonist in preclinical testing to treat obesity and dyslipidemia; and DRF 16536, an AMP-activated protein kinase (AMPK) modulator in preclinical testing to treat dyslipidemia. Perlecan intends to develop compounds through Phase II trials before seeking partners. The newco will have right of first refusal to future NCEs from RDY, and RDY will be offered rights to all NCEs of Perlecan in India, China and Russia and other countries in the Commonwealth of Independent States. ...